TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub
Brought to you by Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA2022 abstracts: What's hot in MPN?

By Marcia Rato,Gizem Karakuleli,Ella Dixon

Share:

Jun 6, 2022

To help navigate the exciting content being presented at the EHA 2022 Congress, the MPN Hub Steering Committee members have provided their recommendations of the top abstracts to look for in the following categories: clinical trial updates, real-world data, MPN and COVID-19, and translational data in MPN.

Clinical trial data

S195

MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor
S196

Ropeginterferon alfa-2b achieves patient-specific treatment goals in polycythemia vera: Final results from the PROUD-PV/CONTINUATION-PV studies
S197

Navitoclax plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study
S198

BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis — JAK inhibitor-naïve or with suboptimal response to ruxolitinib — preliminary data from the manifest study
P1029

Matching-adjusted indirect comparison (MAIC) of pelabresib (CPI-0610) in combination with ruxolitinib vs ruxolitinib or fedratinib monotherapy in patients with intermediate or high-risk myelofibrosis
P1033

A phase 2 study of the LSD1 inhibitor IMG-7289 (bomedemstat) for the treatment of essential thrombocythemia (ET)
P1050

Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]
P1070

Navitoclax monotherapy in patients with myelofibrosis previously treated with JAK-2 inhibitors: Safety and tolerability


Real-word data


MPN and COVID-19


EHA2022 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022

Your opinion matters

On average, how many patients with myelofibrosis do you see in a month?

Newsletter

Subscribe to get the best content delivered to your inbox